Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT05116189 |
| Title | Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) |
| Recruitment | Recruiting |
| Gender | female |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | Merck Sharp & Dohme Corp. |
| Indications | |
| Therapies |
Bevacizumab + Paclitaxel + Pembrolizumab |
| Age Groups: | adult | senior |
| Covered Countries | USA | ITA | FRA | DEU | CAN |